wegovy versus tirzepatide TrimRX Tirzepatide vs. Semaglutide: Which GLP-1

The FDA has also approved Wegovy for adolescents aged 12 years and older who have obesity, defined as: a BMI at or above the 95th percentile for age and sex, based on CDC growth charts Must weigh at least 60 kg (132 lbs) Administered as a once-weekly subcutaneous injection Must be used in conjunction with a reduced-calorie diet and increased physical activity If an adolescent does not achieve at least a 5% reduction in BMI after 12 weeks on the 2.4 mg or maximum tolerated dose, treatment should be discontinued and re-evaluated In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, stroke, and heart attack in adults with cardiovascular disease and either obesity or overweight

Fermented foods and probiotics: the guts new best friend Probiotic-rich foods such as yogurt and kimchi act on gut microbiomes, which modulate GLP-1

It helps regulate blood glucose, slows digestion, and signals fullness to the brain

Apex guarantees that you will receive personalized care with a comprehensive approach, explains Stebbins

SOLIQUA 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use [prescribing information]